DYAI
NASDAQDyadic International Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks39-14%
2025-12-142026-06-07
Mix2190d
- SEC Filings9(43%)
- Other7(33%)
- Earnings4(19%)
- Market1(5%)
Latest news
25 items- SECDyadic International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine DevelopmentJUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company") (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical applications, today announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with Hantavirus Pulmonary Syndrome (HPS), a severe and potentially fat
- PRDyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 10:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/s
- PRSkyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ETNew York, NY, May 21, 2026 (GLOBE NEWSWIRE) -- Skyline Corporate Communications Group, LLC ("Skyline"), an investor relations and corporate communications firm headquartered in New York, today announced that Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic", "the Company"), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, will present at the Skyline Signature Series™ on Wednesday, May 27, 2026. This will be a live, interactive online event inviting investors to ask the company questions in real time. All investors must pre-register. Event: Skyline Signature Series™ Date
- NEWSSidoti Events, LLC's May Micro-Cap Virtual ConferenceNEW YORK, NY / ACCESS Newswire / May 20, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Virtual Investor Conference taking place Wednesday and Thursday, May 20-21, 2026. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links. Presentation Schedule*All Times EDTWednesday, May 20, 2026 (Day 1)8:30-9:00Huize Holding Limited (HUIZ)*****9:15-9:45U Power Limited (UCAR)SuperCom (SPCB)10:00-10:30InTest Corporation (INTT)Dyadic Applied BioSolutions (DYAI)10:45-11:15International Battery Metals (IBATF)A2Z Cust2mate (AZ)11:30
- PRDyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor ConferenceJUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company") (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced that Joe Hazelton, Dyadic's President and Chief Operating Officer, will present at Sidoti's Virtual Investor Conference on May 20-21, 2026. Dyadic's presentation is scheduled to begin at 10:00 a.m. ET on Wednesday, May 20, 2026, and can be accessed live here: Sidoti Webinar Registration. Management will also host virtual one-on-one meetings with investors during the confe
- SECDyadic International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form 10-Q filed by Dyadic International Inc.10-Q - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company ProgressReceived initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industryCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership, while advancing scale-up and commercialization activities for additional recombinant products, including transferrinSigned an OEM distribution agreement with IBT Bioservices to commercialize Dy
- SECSEC Form DEF 14A filed by Dyadic International Inc.DEF 14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form PRE 14A filed by Dyadic International Inc.PRE 14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Dyadic International Inc.10-K/A - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended March 31, 2026 and host a corporate update conference call on Wednesday, May 13, 2026. Conference Call Information Date: Wednesday, May 13, 2026 Time: 5:00 p.m. Eastern Tim
- SECSEC Form 8-K filed by Dyadic International Inc.8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic Announces 2025 Financial Results and Highlights Recent Company ProgressCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnershipSigned an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant DNase I and transferrin for research and cell culture applications through IBT's global distribution channelsEntered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-
- SECDyadic International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form 10-K filed by Dyadic International Inc.10-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT BioservicesJUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer ("OEM") distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices ("IBT"), a life sciences reagent manufacturer and distributor serving global research markets. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT's established sales ch
- PRLife Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,
- PRDyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026. Conference Call Information Date: Wednesday, March 25, 2026 Time: 5:00 p.m. Eastern
- PRLife Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science
- SECSEC Form 8-K filed by Dyadic International Inc.8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form 424B5 filed by Dyadic International Inc.424B5 - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio ("Fermbox"), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools, today announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free). This represents the first commercialized product under the companies expanded collaboration announced
- PRDyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development MilestoneJUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Inzymes ApS ("Inzymes"), a Denmark-based enzyme company specializing in the development, scale-up, and commercialization of enzymes for sustainable food and beverage applications, today announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successful completion
DYAI FAQ
6 questionsWhat does Dyadic International Inc. do?
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen...Where does DYAI stock trade?
Dyadic International Inc. (DYAI) is listed on NASDAQ.What sector and industry is DYAI in?
Dyadic International Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about DYAI?
Dyadic International Inc. has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $300.00 price target on 2025-10-23. Recent price targets range from $300.00 to $700.00.What companies are similar to DYAI?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare DYAI side-by-side with any of them on Quantisnow.How can I track DYAI on Quantisnow?
Quantisnow aggregates Dyadic International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DYAI to receive live email and push alerts on every new disclosure.